Search - tctmd.com

Displaying 121 - 136 of 136

Sort: Relevancy | Date

News CV Team Pro

Featured Cath Lab Pro: Vivian Tamara

January 28, 2019

Presentation CHIP Florida 2019

Hemodynamic Support in Higher Risk PCI: How, When, and Whom to Support

Presenter: Darshan Doshi

January 26, 2019

News Daily News

African-American ACS Patients Less Often Treated With Prasugrel After PCI

Yael L. Maxwell

January 24, 2019

News Daily News

CAD Yes, Symptoms No: More Evidence Needed to Guide Care

Todd Neale

January 16, 2019

News Daily News

Crushing It: Cangrelor and Ticagrelor Can Be Used Together Safely in STEMI, Small Study Hints

Todd Neale

January 14, 2019

News Opinion Fellow Talk

Early CHIP-Trained Fellow in the United States Offers Insights: Sanjog Kalra, MD

Luai Tabaza, MD

January 10, 2019

News Daily News

Unprotected Left Main PCI? US Interventionalists Aren’t Biting (Yet)

Michael O'Riordan

January 08, 2019

News Daily News

Tailoring Antiplatelet Therapy to Bleeding Risk Post-PCI Improves Outcomes and Cuts Costs, Model Suggests

L.A. McKeown

January 08, 2019

News Daily News

Cardiac Complications Are a Common Cause of Readmission Following Endovascular AAA Interventions

Yael L. Maxwell

January 02, 2019

Presentation Cardiovascular Interventions 2018

Left Ventricular Support During High Risk PCI: Expanded Indications, Technique and Outcomes

Presenter: Alok Sharma

October 26, 2018

Partner Content

Contrast-Induced Acute Kidney Injury: Preventive Measures that Work in High Risk Patients - Osprey/Abiomed

November 12, 2019

Partner Content

Treating the Complex Patients: Impella-Enabled Complete Revascularization - Abiomed

November 12, 2019

Video

3 - High Risk PCI with LV Support Current Clinical Evidence

November 1, 2019

Video

» Interview

Dr. C. Michael Gibson Talks With Dr. Usman Baber About the TWILIGHT Thrombogenicity Substudy: Impact of Ticagrelor Alone vs. Ticagrelor Plus Aspirin on Ex-Vivo Blood Thrombogenicity in High-Risk Patients Undergoing PCI

September 28, 2019

Video

» Interview

Dr. C. Michael Gibson Talks With Dr. Roxana Mehran About TWILIGHT: A Randomized Trial of Ticagrelor Monotherapy vs. Ticagrelor Plus Aspirin Beginning at 3 Months in High-Risk Patients Undergoing PCI

September 27, 2019

CME

Advertisement

Featured Cath Lab Pro: Vivian Tamara

Hemodynamic Support in Higher Risk PCI: How, When, and Whom to Support

African-American ACS Patients Less Often Treated With Prasugrel After PCI

CAD Yes, Symptoms No: More Evidence Needed to Guide Care

Crushing It: Cangrelor and Ticagrelor Can Be Used Together Safely in STEMI, Small Study Hints

Early CHIP-Trained Fellow in the United States Offers Insights: Sanjog Kalra, MD

Unprotected Left Main PCI? US Interventionalists Aren’t Biting (Yet)

Tailoring Antiplatelet Therapy to Bleeding Risk Post-PCI Improves Outcomes and Cuts Costs, Model Suggests

Cardiac Complications Are a Common Cause of Readmission Following Endovascular AAA Interventions

Left Ventricular Support During High Risk PCI: Expanded Indications, Technique and Outcomes

Contrast-Induced Acute Kidney Injury: Preventive Measures that Work in High Risk Patients - Osprey/Abiomed

Treating the Complex Patients: Impella-Enabled Complete Revascularization - Abiomed

3 - High Risk PCI with LV Support Current Clinical Evidence

Dr. C. Michael Gibson Talks With Dr. Usman Baber About the TWILIGHT Thrombogenicity Substudy: Impact of Ticagrelor Alone vs. Ticagrelor Plus Aspirin on Ex-Vivo Blood Thrombogenicity in High-Risk Patients Undergoing PCI

Dr. C. Michael Gibson Talks With Dr. Roxana Mehran About TWILIGHT: A Randomized Trial of Ticagrelor Monotherapy vs. Ticagrelor Plus Aspirin Beginning at 3 Months in High-Risk Patients Undergoing PCI

Recent TAVR Updates and Upcoming Studies at ACC 2016

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content